Inhibiteurs

PROTAC PARP/EGFR ligand 1 enables dual PARP EGFR degrader synthesis via PROTAC.

A031: PROTAC AR degrader, IC50 < 0.25 μM, inhibits prostate cancer growth in zebrafish.

Apoptosis Inducer 4 (Compound 12b) is a compound that induces apoptosis and exhibits anticancer properties [1].

ERK1/2 inhibitor 5 targets MAPK pathway, potentially aiding cancer and inflammation research.

CAY10736: Anticancer agent, blocks cell growth & migration in various cancers, effective in mouse models.

PLK1-IN-6: potent, selective PLK1 inhibitor, IC50 = 0.45 nM, hinders cancer cell growth.

PROTAC VEGFR-2 degrader-2 has minimal VEGFR-2 inhibition (IC50 > 1μM) and low anti-proliferative effect on EA.hy926 cells (IC50 > 100μM).

Questiomycin A derivatives 13 is a Questiomycin A derivative.

Antiviral agent 8, surpassing lead compounds crocin-1 and crocin-2, has been identified as a potent and promising candidate with enhanced antiviral activities.

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a cereblon ligand-PEG linker for PROTAC, is synthesized.

Patecibart is a humanized immunoglobulin G4-kappa monoclonal antibody that functions as an antagonist to the endothelin receptor A (EDNRA).